Human three prime exonuclease TREX1 is induced by genotoxic stress and involved in protection of glioma and melanoma cells to anticancer drugs

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 8, 2013, Pages 1832-1843

  Tomicic, Maja T ^a   Aasland, Dorthe ^a   Nikolova, Teodora ^a   Kaina, Bernd ^a   Christmann, Markus ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Anticancer drug; AP 1; Glioma; Melanoma; Transcriptional regulation; TREX1

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; EXONUCLEASE; FOTEMUSTINE; MESSENGER RNA; NIMUSTINE; SMALL INTERFERING RNA; TEMOZOLOMIDE; TOPOTECAN;

ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL DEATH; CROSS LINKING; DNA DAMAGE; DOWN REGULATION; DRUG SENSITIVITY; GENE MUTATION; GENOTOXICITY; GLIOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; MELANOMA; ONCOGENE C FOS; PRIORITY JOURNAL; ULTRAVIOLET RADIATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL DEATH; CELL LINE; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EXODEOXYRIBONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, JUN; GLIOMA; HUMANS; MELANOMA; MUTATION; PHOSPHOPROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-FOS; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84877800180     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.03.029     Document Type: Article

References (48)

1. Christmann M., Tomicic M.T., Roos W.P., Kaina B. Mechanisms of human DNA repair: an update. Toxicology 2003, 193:3-34.
2. Mazur D.J., Perrino F.W. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3'→5' exonucleases. J. Biol. Chem. 1999, 274:19655-19660.
3. Mazur D.J., Perrino F.W. Excision of 3' termini by the Trex1 and TREX2 3'→5' exonucleases. Characterization of the recombinant proteins. J. Biol. Chem. 2001, 276:17022-17029.
4. Crow Y.J., Hayward B.E., Parmar R., Robins P., Leitch A., Ali M., Black D.N., van Bokhoven H., Brunner H.G., Hamel B.C., Corry P.C., Cowan F.M., Frints S.G., Klepper J., Livingston J.H., Lynch S.A., Massey R.F., Meritet J.F., Michaud J.L., Ponsot G., Voit T., Lebon P., Bonthron D.T., Jackson A.P., Barnes D.E., Lindahl T. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat. Genet. 2006, 38:917-920.
5. Rice G., Newman W.G., Dean J., Patrick T., Parmar R., Flintoff K., Robins P., Harvey S., Hollis T., O'Hara A., Herrick A.L., Bowden A.P., Perrino F.W., Lindahl T., Barnes D.E., Crow Y.J. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am. J. Hum. Genet. 2007, 80:811-815.
6. Richards A., van den Maagdenberg A.M., Jen J.C., Kavanagh D., Bertram P., Spitzer D., Liszewski M.K., Barilla-Labarca M.L., Terwindt G.M., Kasai Y., McLellan M., Grand M.G., Vanmolkot K.R., de Vries B., Wan J., Kane M.J., Mamsa H., Schafer R., Stam A.H., Haan J., de Jong P.T., Storimans C.W., van Schooneveld M.J., Oosterhuis J.A., Gschwendter A., Dichgans M., Kotschet K.E., Hodgkinson S., Hardy T.A., Delatycki M.B., Hajj-Ali R.A., Kothari P.H., Nelson S.F., Frants R.R., Baloh R.W., Ferrari M.D., Atkinson J.P. C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat. Genet. 2007, 39:1068-1070.
7. Lee-Kirsch M.A., Gong M., Chowdhury D., Senenko L., Engel K., Lee Y.A., de Silva U., Bailey S.L., Witte T., Vyse T.J., Kere J., Pfeiffer C., Harvey S., Wong A., Koskenmies S., Hummel O., Rohde K., Schmidt R.E., Dominiczak A.F., Gahr M., Hollis T., Perrino F.W., Lieberman J., Hubner N. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 2007, 39:1065-1067.
8. Lee-Kirsch M.A., Chowdhury D., Harvey S., Gong M., Senenko L., Engel K., Pfeiffer C., Hollis T., Gahr M., Perrino F.W., Lieberman J., Hubner N. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J. Mol. Med. 2007, 85:531-537.
9. Morita M., Stamp G., Robins P., Dulic A., Rosewell I., Hrivnak G., Daly G., Lindahl T., Barnes D.E. Gene-targeted mice lacking the Trex1 (DNase III) 3'→5' DNA exonuclease develop inflammatory myocarditis. Mol. Cell. Biol. 2004, 24:6719-6727.
10. Stetson D.B., Ko J.S., Heidmann T., Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134:587-598.
11. Fye J.M., Orebaugh C.D., Coffin S.R., Hollis T., Perrino F.W. Dominant mutation of the TREX1 exonuclease gene in lupus and Aicardi-Goutieres syndrome. J. Biol. Chem. 2011, 286:32373-32382.
12. Lehtinen D.A., Harvey S., Mulcahy M.J., Hollis T., Perrino F.W. The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease. J. Biol. Chem. 2008, 283:31649-31656.
13. Chowdhury D., Beresford P.J., Zhu P., Zhang D., Sung J.S., Demple B., Perrino F.W., Lieberman J. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol. Cell 2006, 23:133-142.
14. Yan N., Cherepanov P., Daigle J.E., Engelman A., Lieberman J. The SET complex acts as a barrier to autointegration of HIV-1. PLoS Pathog. 2009, 5:e1000327.
15. Yan N., Regalado-Magdos A.D., Stiggelbout B., Lee-Kirsch M.A., Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 2011, 11:1005-1013.
16. Yang Y.G., Lindahl T., Barnes D.E. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 2007, 131:873-886.
17. Christmann M., Tomicic M.T., Aasland D., Berdelle N., Kaina B. Three prime exonuclease I (TREX1) is Fos/AP-1 regulated by genotoxic stress and protects against ultraviolet light and benzo(a)pyrene-induced DNA damage. Nucleic Acids Res. 2010, 38:6418-6432.
18. Naumann S.C., Roos W.P., Jost E., Belohlavek C., Lennerz V., Schmidt C.W., Christmann M., Kaina B. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br. J. Cancer 2009, 100:322-333.
19. Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 2003, 22:8233-8245.
20. Christmann M., Kaina B. Nuclear translocation of mismatch repair proteins MSH2 and MSH6 as a response of cells to alkylating agents. J. Biol. Chem. 2000, 275:36256-36262.
21. Tomicic M.T., Bey E., Wutzler P., Thust R., Kaina B. Comparative analysis of DNA breakage, chromosomal aberrations and apoptosis induced by the anti-herpes purine nucleoside analogues aciclovir, ganciclovir and penciclovir. Mutat. Res. 2002, 505:1-11.
22. Tomicic M.T., Friedrichs C., Christmann M., Wutzler P., Thust R., Kaina B. Apoptosis induced by (E)-5-(2-bromovinyl)-2'-deoxyuridine in varicella zoster virus thymidine kinase-expressing cells is driven by activation of c-Jun/activator protein-1 and Fas ligand/caspase-8. Mol. Pharmacol. 2003, 63:439-449.
23. Tomicic M.T., Reischmann P., Rasenberger B., Meise R., Kaina B., Christmann M. Delayed c-Fos activation in human cells triggers XPF induction and an adaptive response to UVC-induced DNA damage and cytotoxicity. Cell. Mol. Life Sci. 2011, 68:1785-1798.
24. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur. J. Cancer 2005, 41:2449-2461.
25. Durchdewald M., Angel P., Hess J. The transcription factor Fos: a Janus-type regulator in health and disease. Histol. Histopathol. 2009, 24:1451-1461.
26. De Rossi A., Rossi L., Laudisi A., Sini V., Toppo L., Marchesi F., Tortorelli G., Leti M., Turriziani M., Aquino A., Bonmassar E., De Vecchis L., Torino F. Focus on fotemustine. J. Exp. Clin. Cancer Res. 2006, 25:461-468.
27. Serra M., Forcales S.V., Pereira-Lopes S., Lloberas J., Celada A. Characterization of Trex1 induction by IFN-gamma in murine macrophages. J. Immunol. 2011, 186:2299-2308.
28. Wang C.J., Lam W., Bussom S., Chang H.M., Cheng Y.C. TREX1 acts in degrading damaged DNA from drug-treated tumor cells. DNA Repair (Amst) 2009, 8:1179-1189.
29. Ochs K., Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res. 2000, 60:5815-5824.
30. Roos W.P., Kaina B. DNA damage-induced apoptosis: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013.
31. Sherman M.L., Datta R., Hallahan D.E., Weichselbaum R.R., Kufe D.W. Ionizing radiation regulates expression of the c-Jun protooncogene. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:5663-5666.
32. Liu Z.G., Baskaran R., Lea-Chou E.T., Wood L.D., Chen Y., Karin M., Wang J.Y. Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 1996, 384:273-276.
33. Dosch J., Kaina B. Induction of c-fos, c-Jun, junB and junD mRNA and AP-1 by alkylating mutagens in cells deficient and proficient for the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) and its relationship to cell death, mutation induction and chromosomal instability. Oncogene 1996, 13:1927-1935.
34. Tomicic M.T., Christmann M., Kaina B. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Cancer Res. 2005, 65:8920-8926.
35. Tomicic M.T., Christmann M., Kaina B. Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. J. Pharmacol. Exp. Ther. 2010, 332:316-325.
36. Tomicic M.T., Kaina B. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Biochim. Biophys. Acta 2012, 1835:11-27.
37. Dunkern T.R., Kaina B. Cell proliferation and DNA breaks are involved in ultraviolet light-induced apoptosis in nucleotide excision repair-deficient Chinese hamster cells. Mol. Biol. Cell 2002, 13:348-361.
38. Goldstein M., Roos W.P., Kaina B. Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling. Toxicol. Appl. Pharmacol. 2008, 229:20-32.
39. Meise R., Tomicic M.T., Kaina B., Christmann M. The chloroethylating anticancer drug ACNU induces FRA1 that is involved in drug resistance of glioma cells. Biochim. Biophys. Acta 2012, 1823:1199-1207.
40. Kim J.H., Kim H.D., Ryu G.H., Kim D.H., Hurwitz J., Seo Y.S. Isolation of human Dna2 endonuclease and characterization of its enzymatic properties. Nucleic Acids Res. 2006, 34:1854-1864.
41. Masuda-Sasa T., Imamura O., Campbell J.L. Biochemical analysis of human Dna2. Nucleic Acids Res. 2006, 34:1865-1875.
42. Bambara R.A., Murante R.S., Henricksen L.A. Enzymes and reactions at the eukaryotic DNA replication fork. J. Biol. Chem. 1997, 272:4647-4650.
43. Crow Y.J., Leitch A., Hayward B.E., Garner A., Parmar R., Griffith E., Ali M., Semple C., Aicardi J., Babul-Hirji R., Baumann C., Baxter P., Bertini E., Chandler K.E., Chitayat D., Cau D., Dery C., Fazzi E., Goizet C., King M.D., Klepper J., Lacombe D., Lanzi G., Lyall H., Martinez-Frias M.L., Mathieu M., McKeown C., Monier A., Oade Y., Quarrell O.W., Rittey C.D., Rogers R.C., Sanchis A., Stephenson J.B., Tacke U., Till M., Tolmie J.L., Tomlin P., Voit T., Weschke B., Woods C.G., Lebon P., Bonthron D.T., Ponting C.P., Jackson A.P. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat. Genet. 2006, 38:910-916.
44. Arudchandran A., Cerritelli S., Narimatsu S., Itaya M., Shin D.Y., Shimada Y., Crouch R.J. The absence of ribonuclease H1 or H2 alters the sensitivity of Saccharomyces cerevisiae to hydroxyurea, caffeine and ethyl methanesulphonate: implications for roles of RNases H in DNA replication and repair. Genes Cells 2000, 5:789-802.
45. Qiu J., Qian Y., Frank P., Wintersberger U., Shen B. Saccharomyces cerevisiae RNase H(35) functions in RNA primer removal during lagging-strand DNA synthesis, most efficiently in cooperation with Rad27 nuclease. Mol. Cell. Biol. 1999, 19:8361-8371.
46. Reijns M.A., Rabe B., Rigby R.E., Mill P., Astell K.R., Lettice L.A., Boyle S., Leitch A., Keighren M., Kilanowski F., Devenney P.S., Sexton D., Grimes G., Holt I.J., Hill R.E., Taylor M.S., Lawson K.A., Dorin J.R., Jackson A.P. Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development. Cell 2012, 149:1008-1022.
47. Bailey S.L., Harvey S., Perrino F.W., Hollis T. Defects in DNA degradation revealed in crystal structures of TREX1 exonuclease mutations linked to autoimmune disease. DNA Repair (Amst) 2012, 11:65-73.
48. Orebaugh C.D., Fye J.M., Harvey S., Hollis T., Perrino F.W. The TREX1 exonuclease R114H mutation in Aicardi-Goutieres syndrome and lupus reveals dimeric structure requirements for DNA degradation activity. J. Biol. Chem. 2011, 286:40246-40254.